SWOG clinical trial number
SWOG-9239

Phase II Trial of Sequential Modification of Immunosuppression, Interferon Alpha, and ProMACE-CytaBOM for Treatment of Post-Organ Transplant Lymphoproliferation

Closed
Phase
Accrual
40%
Published
Abbreviated Title
Post-Organ Transplant Lymphoproliferation Treatment
Activated
04/15/1995
Closed
08/15/2000
Participants
NCORP, Members, Medical Oncologists, Pathologists, ECOG

Research committees

Lymphoma

Treatment

Alpha Interferon ProMACE-CytaBOM

Eligibility Criteria Expand/Collapse

Biopsy proven post-transplantation lymphoproliferation; cardiac, renal, liver allograft recipient; no BMT recipients; bidimen. meas.; if pt requires an intra-aortic balloon pump, it must be for either acute rejection or lymphoma-heart involvement; no prior chemo or IFN for post-transplant lymph.; no CNS involvement as sole site
of disease; no AIDS or HIV.

Publication Information Expand/Collapse

2008

Prospective study of sequential reduction in immunosuppression, interferon alpha-2B, and chemotherapy for post-transplantation lymphoproliferative disorder (PTLD) [PMID: 18645482]

LJ Swinnen;M LeBlanc;TM Grogan;LI Gordon;PJ Stiff;AM Miller;Y Kasamon;TP Miller;RI Fisher Transplantation 86(2):215-222

2003

Tumor Origin and CD20 expression in posttransplant lymphoproliferative disorder occurring in solid organ transplant recipients: implications for immune-based therapy

ML Gulley;LJ Swinnen;KT Plaisance Jr;C Schnell;TM Grogan;BG Schneider Transplantation 76(6):959-964

Phase II study of sequential reduction in immunosuppression, interferon alpha-2b, and ProMACE-CytaBOM chemotherapy for post-transplant lymphoproliferative disorder (PTLD) (SWOG/ECOG S9239)

LJ Swinnen;M LeBlanc;Y Kasamon;T Grogan;L Gordon;TP Miller;RI Fisher Blood 102(11):403a (#1463)

1999

Frequent expression of hte tumor necrosis factor receptor associated factor-1 in LMP1-positive post transplant lymphoproliferative disease and HIV-associated lymphomas

PG Murray;LJ Swinnen;JR Flavell;MV Ragni;HT Hassan;D Lowe;C Schnell;J Johl;LS Young;RF Ambinder Blood 94(10)Suppl.1:303a(#1353)part_1_of_2

Bcl-6 is not overexpressed in post-transplant lymphoproliferative disorder (PTLD)

CC Ye;LJ Swinnen;H Fan;TM Grogan;ML Gulley Blood 94(10)Suppl.1:519a(#2322)part_1_of_2

1998

EBV DNA quantitation in serum is highly correlated with the development and regression of post-transplant lymphoproliferative disorder (PTLD) in solid organ tranplant recipients.

LJ Swinnen;ML Gulley;E Hamilton;SA Schichman Blood 92(10)(Suppl.1):314a-315a(#1291)

To the editor-in-chief.

Q Tao;RF Ambinder;LJ Swinnen American Journal of Pathology 152(5):1398-1399

1997

Conservation of Epstein-Barr virus (EBV) CTL epitopes in EVB(+) post transplant lymphomas in solid organ transplant recipients.

Q Tao;LD Swinnen;RF Ambinder Blood 90(10)(Supl.1):512a(#2281)

Other Clinical Trials

SWOG Clinical Trial Number
S2207

Randomized Phase II Study of the Addition of Targeted Therapeutic Agents to Tafasitamab-Based Therapy in Non-Transplant-Eligible Patients with Relapse/Refractory Large B-Cell Lymphoma
Research Committee(s)
Lymphoma
Activated
06/30/2023
Accrual
6%
Open
Phase
SWOG Clinical Trial Number
CTSU/AHOD2131

A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy with Immuno-oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma
Research Committee(s)
Lymphoma
Immunomolecular Therapeutics
Activated
04/28/2023
Open
Phase
SWOG Clinical Trial Number
S2114

A Randomized Phase II trial of consolidation therapy following CD19 CAR T-cell treatment for Relapsed/Refractory Diffuse Large B-cell Lymphoma or Grade IIIB Follicular Lymphoma
Research Committee(s)
Lymphoma
Activated
02/23/2023
Accrual
11%
Open
Phase